{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:50:15Z","timestamp":1794102615064,"version":"4.8.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cyclin D1 (CCND1) is a well-known regulator of cell-cycle progression. It is overexpressed in several types of cancer including breast, lung, squamous, neuroblastoma, and lymphomas. The most well-known mechanism of overexpression is the t(11;14)(q13;q32) translocation found in mantle cell lymphoma (MCL). It has previously been shown that truncated CCND1 mRNA in MCL correlates with poor prognosis. We hypothesized that truncations of the CCND1 mRNA alter its ability to be down-regulated by microRNAs in MCL. MicroRNAs are a new class of abundant small RNAs that play important regulatory roles at the posttranscriptional level by binding to the 3\u2032 untranslated region (UTR) of mRNAs blocking either their translation or initiating their degradation. In this study, we have identified the truncation in CCND1 mRNA in MCL cell lines. We also found that truncated CCND1 mRNA leads to increased CCND1 protein expression and increased S-phase cell fraction. Furthermore, we demonstrated that this truncation alters miR-16-1 binding sites, and through the use of reporter constructs, we were able to show that miR-16-1 regulates CCND1 mRNA expression. This study introduces the role of miR-16-1 in the regulation of CCND1 in MCL.<\/jats:p>","DOI":"10.1182\/blood-2008-03-142182","type":"journal-article","created":{"date-parts":[[2008,5,16]],"date-time":"2008-05-16T01:31:58Z","timestamp":1210901518000},"page":"822-829","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":160,"title":["Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma"],"prefix":"10.1182","volume":"112","author":[{"given":"Robert W.","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne T.","family":"Bemis","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M.","family":"Amato","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Myint","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Tran","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane K.","family":"Birks","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Gail","family":"Eckhardt","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111721304373200_B1","first-page":"115","article-title":"Mantle-cell lymphoma.","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol"},{"key":"2019111721304373200_B2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007.","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"2019111721304373200_B3","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma.","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111721304373200_B4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.767","article-title":"Update on the molecular biology of mantle cell lymphoma.","volume":"24","author":"Bertoni","year":"2006","journal-title":"Hematol Oncol"},{"key":"2019111721304373200_B5","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1101\/gad.7.8.1559","article-title":"Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.","volume":"7","author":"Quelle","year":"1993","journal-title":"Genes Dev"},{"key":"2019111721304373200_B6","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1128\/MCB.14.3.1669","article-title":"Acceleration of the G1\/S phase transition by expression of cyclins D1 and E with an inducible system.","volume":"14","author":"Resnitzky","year":"1994","journal-title":"Mol Cell Biol"},{"key":"2019111721304373200_B7","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.onc.1209371","article-title":"Cyclin D1: polymorphism, aberrant splicing and cancer risk.","volume":"25","author":"Knudsen","year":"2006","journal-title":"Oncogene"},{"key":"2019111721304373200_B8","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1101\/gad.12.22.3499","article-title":"Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.","volume":"12","author":"Diehl","year":"1998","journal-title":"Genes Dev"},{"key":"2019111721304373200_B9","first-page":"7056","article-title":"An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene.","volume":"63","author":"Lu","year":"2003","journal-title":"Cancer Res"},{"key":"2019111721304373200_B10","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"2019111721304373200_B11","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.","volume":"101","author":"Calin","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111721304373200_B12","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1093\/emboj\/cdf476","article-title":"MicroRNA maturation: stepwise processing and subcellular localization.","volume":"21","author":"Lee","year":"2002","journal-title":"Embo J"},{"key":"2019111721304373200_B13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","article-title":"Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.","volume":"120","author":"Lewis","year":"2005","journal-title":"Cell"},{"key":"2019111721304373200_B14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","article-title":"Prediction of mammalian microRNA targets.","volume":"115","author":"Lewis","year":"2003","journal-title":"Cell"},{"key":"2019111721304373200_B15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.beha.2007.02.003","article-title":"The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia.","volume":"20","author":"Calin","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111721304373200_B16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg1990","article-title":"The evolution of gene regulation by transcription factors and microRNAs.","volume":"8","author":"Chen","year":"2007","journal-title":"Nat Rev Genet"},{"key":"2019111721304373200_B17","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","article-title":"A microRNA component of the p53 tumour suppressor network.","volume":"447","author":"He","year":"2007","journal-title":"Nature"},{"key":"2019111721304373200_B18","doi-asserted-by":"crossref","first-page":"11755","DOI":"10.1073\/pnas.0404432101","article-title":"MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.","volume":"101","author":"Calin","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111721304373200_B19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.","volume":"353","author":"Calin","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111721304373200_B20","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2.","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111721304373200_B21","unstructured":"Whitehead Institute for Biomedical Research Target Scan. Accessed April 1, 2008 http:\/\/www.targetscan.org"},{"key":"2019111721304373200_B22","unstructured":"New York University Center for Comparative Functional Genomics Max Delbr\u00fcck Center for Molecular Medicine. PicTar Accessed April 1, 2008 http:\/\/pictar.bio.nyu.edu\/"},{"key":"2019111721304373200_B23","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1128\/MCB.02005-06","article-title":"Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression.","volume":"27","author":"Linsley","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2019111721304373200_B24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","article-title":"Characterization of 4 mantle cell lymphoma cell lines.","volume":"127","author":"Amin","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"2019111721304373200_B25","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","article-title":"Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.","volume":"105","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"key":"2019111721304373200_B26","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2004-07-2730","article-title":"Novel chromsomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization.","volume":"105","author":"Schraders","year":"2005","journal-title":"Blood"},{"key":"2019111721304373200_B27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.leukres.2005.11.013","article-title":"Genomic imbalances and patterns of karyotypic variabliity in mantle-cell lymphoma cell lines.","volume":"30","author":"Camps","year":"2006","journal-title":"Leuk Res"},{"key":"2019111721304373200_B28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2007.06.017","article-title":"MicroRNA targeting specificity in mammals: determinants beyond seed pairing.","volume":"27","author":"Grimson","year":"2007","journal-title":"Mol Cell"},{"key":"2019111721304373200_B29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1126\/science.1091903","article-title":"MicroRNAs modulate hematopoietic lineage differentiation.","volume":"303","author":"Chen","year":"2004","journal-title":"Science"},{"key":"2019111721304373200_B30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-005-9066-y","article-title":"Validation of cyclin D1\/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.","volume":"95","author":"Grillo","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"2019111721304373200_B31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/cbt.4.3.1504","article-title":"Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin.","volume":"4","author":"Oridate","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"2019111721304373200_B32","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1158\/1078-0432.CCR-05-1213","article-title":"Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization.","volume":"12","author":"Yasui","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2019111721304373200_B33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"2019111721304373200_B34","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"key":"2019111721304373200_B35","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111721304373200_B36","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111721304373200_B37","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.3816\/CLM.2006.s.005","article-title":"New directions in the treatment of mantle cell lymphoma: an overview.","volume":"7","author":"Goy","year":"2006","journal-title":"Clin Lymphoma Myeloma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/3\/822\/1305338\/zh801508000822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/3\/822\/1305338\/zh801508000822.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T19:04:41Z","timestamp":1631300681000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/3\/822\/25259\/Truncation-in-CCND1-mRNA-alters-miR161-regulation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-03-142182","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}